JP6002040B2 - 低メチル化剤及びヒストン脱アセチル化酵素阻害剤を含む薬学的組成物 - Google Patents

低メチル化剤及びヒストン脱アセチル化酵素阻害剤を含む薬学的組成物 Download PDF

Info

Publication number
JP6002040B2
JP6002040B2 JP2012541988A JP2012541988A JP6002040B2 JP 6002040 B2 JP6002040 B2 JP 6002040B2 JP 2012541988 A JP2012541988 A JP 2012541988A JP 2012541988 A JP2012541988 A JP 2012541988A JP 6002040 B2 JP6002040 B2 JP 6002040B2
Authority
JP
Japan
Prior art keywords
transdermal
patch
cladribine
reservoir
hdaci
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012541988A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013512898A (ja
JP2013512898A5 (enExample
Inventor
エリオット エム． エプネー
エリオット エム． エプネー
ルーク エム． ヴォーン
ルーク エム． ヴォーン
Original Assignee
ニンブル エピテック リミテッド ライアビリティ カンパニー
ニンブル エピテック リミテッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニンブル エピテック リミテッド ライアビリティ カンパニー, ニンブル エピテック リミテッド ライアビリティ カンパニー filed Critical ニンブル エピテック リミテッド ライアビリティ カンパニー
Publication of JP2013512898A publication Critical patent/JP2013512898A/ja
Publication of JP2013512898A5 publication Critical patent/JP2013512898A5/ja
Application granted granted Critical
Publication of JP6002040B2 publication Critical patent/JP6002040B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012541988A 2009-12-02 2010-04-30 低メチル化剤及びヒストン脱アセチル化酵素阻害剤を含む薬学的組成物 Expired - Fee Related JP6002040B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US28330509P 2009-12-02 2009-12-02
US61/283,305 2009-12-02
US30195610P 2010-02-05 2010-02-05
US61/301,956 2010-02-05
US32008310P 2010-04-01 2010-04-01
US61/320,083 2010-04-01
US12/769,913 2010-04-29
US12/769,913 US8491927B2 (en) 2009-12-02 2010-04-29 Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
PCT/US2010/001287 WO2011068522A1 (en) 2009-12-02 2010-04-30 Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor

Publications (3)

Publication Number Publication Date
JP2013512898A JP2013512898A (ja) 2013-04-18
JP2013512898A5 JP2013512898A5 (enExample) 2013-06-20
JP6002040B2 true JP6002040B2 (ja) 2016-10-05

Family

ID=44069079

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012541988A Expired - Fee Related JP6002040B2 (ja) 2009-12-02 2010-04-30 低メチル化剤及びヒストン脱アセチル化酵素阻害剤を含む薬学的組成物

Country Status (9)

Country Link
US (3) US8491927B2 (enExample)
EP (1) EP2506814A4 (enExample)
JP (1) JP6002040B2 (enExample)
KR (1) KR20120127580A (enExample)
CN (1) CN102711686A (enExample)
AU (1) AU2010326699B2 (enExample)
CA (1) CA2782205A1 (enExample)
MX (1) MX2012006128A (enExample)
WO (1) WO2011068522A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8491927B2 (en) * 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
AU2013234955A1 (en) 2012-03-23 2014-11-13 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
WO2013162054A1 (ja) * 2012-04-24 2013-10-31 公立大学法人首都大学東京 クロマチン構造を制御する組成物
JP6243102B2 (ja) * 2012-05-01 2017-12-06 株式会社ジェムインターナショナル 貼付剤
FR2993461B1 (fr) 2012-07-19 2014-08-08 Genethon Utilisation de composes modifiant l'epigenome pour le traitement des maladies genetiques musculaires liees a une anomalie de conformation proteique
WO2014022524A1 (en) * 2012-07-31 2014-02-06 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
US20140142522A1 (en) * 2012-11-16 2014-05-22 NU Technology, LLC Moist dressing with honeycomb pattern and drain channels
CN114099686B (zh) * 2014-07-15 2024-04-16 约翰·霍普金斯大学 源自骨髓的抑制细胞的抑制和免疫检查点阻断
US9962340B2 (en) 2015-06-09 2018-05-08 Life Tech Global, Llc Device and method for the transdermal delivery of cannabidiol
US10272125B2 (en) * 2015-09-14 2019-04-30 Life Tech Global, Llc Transdermal delivery of cannabidiol with other active moieties including cannabinoids
JP7373991B2 (ja) 2016-07-15 2023-11-06 ビラクタ セラピューティクス，インク． 免疫療法で使用するためのヒストン脱アセチル化酵素阻害剤
US20180353446A1 (en) * 2017-06-07 2018-12-13 Ranedis Pharmaceuticals, Llc Compositions and methods of treating and/or preventing cancer
MX2021014639A (es) 2019-05-31 2022-04-06 Viracta Subsidiary Inc Metodos para tratar canceres asociados con virus con inhibidores de la histona deacetilasa.
TW202128169A (zh) * 2019-10-07 2021-08-01 美商維拉克塔治療公司 具有降低副作用之hdac治療劑量
US20220087948A1 (en) * 2020-09-18 2022-03-24 Nanovibronix, Inc. Transdermal patch of a portable ultrasound-generating system for improved delivery of therapeutic agents and associated methods of treatment

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
JPS62126123A (ja) * 1985-11-28 1987-06-08 Shigeki Suzuki バルプロ酸の経皮吸収方法
JPH06510290A (ja) * 1991-08-27 1994-11-17 シグナス，インコーポレイテッド プラゾシンを投与するための経皮処方物
AU701737B2 (en) 1995-04-07 1999-02-04 Novartis Ag Iontophoretic transdermal system for the administration of at least two substances
US5736154A (en) 1996-03-11 1998-04-07 Fuisz Technologies Ltd. Transdermal delivery system
FR2749514B1 (fr) 1996-06-11 1998-08-07 Hoechst Marion Roussel Systemes transdermiques renfermant 2 principes actifs dans des compartiments separes, leur procede de preparation et leur application comme medicament
US6479074B2 (en) 1996-10-24 2002-11-12 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
WO1998031369A1 (fr) 1997-01-16 1998-07-23 Sekisui Chemical Co., Ltd. Preparations a usage externe a absorption percutanee
EP1093348A4 (en) 1998-06-29 2003-07-16 Pharmaceuticals Applic Asociat TRANSDERMAL ANALGESIC COMPOSITIONS AND METHODS OF ADMINISTRATION
AU780454B2 (en) 1999-06-03 2005-03-24 Jessie L.S. Au Methods and compositions for modulating cell proliferation and cell death
IL138686A0 (en) 1999-10-01 2001-10-31 Pfizer Prod Inc α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS
AU7788701A (en) * 2000-07-14 2002-01-30 Transform Pharmaceuticals Inc System and method for optimizing tissue barrier transfer of compounds
US6682757B1 (en) 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
EP1293205A1 (en) 2001-09-18 2003-03-19 G2M Cancer Drugs AG Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
BR0215102A (pt) * 2001-12-13 2004-11-03 Vital Health Sciences Pty Ltd Transporte transdermal de compostos, formulação tópica, método para melhorar a absorção da pele, método para a terapia de reposição hormonal, uso de um ou mais derivados de fosfato de um composto hidróxi farmacêutico em um sistema de aplicação transdermal, sistema de aplicação transdermal, método para aplicação de um composto hidróxi farmacêutico a um indivìduo e para melhorar a eficácia de uma formulação
US6841565B1 (en) * 2002-03-29 2005-01-11 The Ohio State University Treatment of patients with chronic lymphocytic leukemia
US7652061B2 (en) 2003-05-20 2010-01-26 Novartis A.G. N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors
JP2009513523A (ja) 2003-07-08 2009-04-02 ノバルティス アクチエンゲゼルシャフト ベンゼンスルホニルアミノ化合物およびそれらを含む医薬組成物
US20050059682A1 (en) 2003-09-12 2005-03-17 Supergen, Inc., A Delaware Corporation Compositions and methods for treatment of cancer
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
EP1689702B1 (en) 2003-11-26 2013-01-30 Novartis AG Organic compounds
WO2005065668A2 (en) 2003-12-29 2005-07-21 Qlt Usa, Inc. Topical compositions comprising halo-deoxyadenosines for treatment of skin disorders
WO2005105009A1 (en) 2004-04-26 2005-11-10 Cassel Douglas R Wound treatment patch for alleviating pain
KR100602434B1 (ko) 2004-09-10 2006-07-19 최상식 복수 개의 단위 구획을 포함하는 약물의 경피 투여용 패치
CA2619568A1 (en) 2005-08-19 2007-03-01 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Topical formulations of histone deacetylase inhibitors and methods of using the same
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US20070197957A1 (en) 2005-10-03 2007-08-23 Hunter William L Implantable sensors, implantable pumps and anti-scarring drug combinations
BRPI0520686A2 (pt) 2005-11-16 2009-05-19 Univ Mexico Nacional Autonoma uso de agentes modificantes de transcriptoma associado a quimioterapia ou radioterapia contra o cáncer
EP3000480A1 (en) 2005-12-01 2016-03-30 ProNAi Therapeutics, Inc. Cancer therapies and pharmaceutical compositions used therein
WO2007067695A2 (en) 2005-12-07 2007-06-14 University Of Utah Research Foundation Dna methylation as a target for diagnosis and treatment of chronic lymphocytic leukemia (cll)
JP5468782B2 (ja) 2006-03-02 2014-04-09 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 癌治療と幹細胞調節のための方法
US8585753B2 (en) 2006-03-04 2013-11-19 John James Scanlon Fibrillated biodegradable prosthesis
WO2007109178A2 (en) 2006-03-16 2007-09-27 Pharmacyclics, Inc. Indole derivatives as inhibitors of histone deacetylase
ES2444890T3 (es) 2006-03-31 2014-02-27 Erasmus University Medical Center Rotterdam Nueva composición para el control del crecimiento tumoral
ATE516020T1 (de) * 2006-05-05 2011-07-15 Coloplast As Haftklebstoffzusammensetzung, enthaltend vernetztes polyalkylenoxid und wasserabsorbierende hydrophile mittel
WO2008082646A2 (en) 2006-12-28 2008-07-10 The Johns Hopkins University Histone deacetylase inhibitors, combination therapies and methods of use
EP2491923A3 (en) 2007-02-15 2012-12-26 Novartis AG Combinations of therapeutic agents for treating cancer
WO2008116163A1 (en) 2007-03-22 2008-09-25 Oregon Health & Science University Therapeutic drug combinations for treatment of b-cell malignancies
WO2008127735A1 (en) 2007-04-13 2008-10-23 Stemline Therapeutics, Inc. Il3ralpha antibody conjugates and uses thereof
US20090025274A1 (en) 2007-07-23 2009-01-29 Tim Lail Animal trap
US8216571B2 (en) 2007-10-22 2012-07-10 Schering Corporation Fully human anti-VEGF antibodies and methods of using
WO2009067543A2 (en) 2007-11-19 2009-05-28 The Regents Of The University Of Colorado Treatment of histone deacetylase mediated disorders
WO2009067453A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Combinations of hdac inhibitors and proteasome inhibitors
HUE055911T2 (hu) 2008-05-15 2021-12-28 Celgene Corp Citidin-analógokat tartalmazó orális készítmények, és eljárások azok alkalmazására
WO2009155477A1 (en) 2008-06-19 2009-12-23 The Trustees Of The University Of Pennsylvania Inducible regulatory t-cell generation for hematopoietic transplants
WO2010020787A1 (en) 2008-08-22 2010-02-25 Oncomethylome Sciences Sa Diagnosis and treatment of tumours
DK2433124T3 (en) * 2009-05-19 2017-06-19 Vivia Biotech Sl PROCEDURES FOR PROVIDING PERSONALIZED MEDICAL EX VIVO TESTS FOR HEMATOLOGICAL NEOPLASMS
US8491927B2 (en) * 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
JP5548470B2 (ja) * 2010-02-16 2014-07-16 日本碍子株式会社 ハニカム触媒体
US20110245154A1 (en) * 2010-03-11 2011-10-06 Hemaquest Pharmaceuticals, Inc. Methods and Compositions for Treating Viral or Virally-Induced Conditions
EP2382993A1 (en) * 2010-04-19 2011-11-02 KTB Tumorforschungsgesellschaft mbH Combination of drugs with protein-binding prodrugs
WO2012044936A1 (en) * 2010-09-30 2012-04-05 Portola Pharmaceuticals, Inc. Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide
DK2786753T3 (en) * 2010-11-12 2019-04-15 Pharma Mar Sa Combination therapy with an antitumor antibiotic
US20130004481A1 (en) * 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
JP2014513079A (ja) * 2011-04-08 2014-05-29 アフラクシス・ホールディングス・インコーポレイテッド 神経系疾患及び癌の治療のための８−エチル−６−（アリール）ピリド［２，３−ｄ］ピリミジン−７（８ｈ）−オン
US10941399B2 (en) * 2011-04-14 2021-03-09 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for gene-specific demethylation by DNA methyltransferase (DNMT)-RNA interaction
US20140170148A1 (en) * 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2
JP2014519813A (ja) * 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
BR112013033534A2 (pt) * 2011-06-28 2017-02-07 Pharmacyclics Inc métodos e composições para inibição de reabsorção de osso
TW201700103A (zh) * 2011-11-01 2017-01-01 西建公司 利用胞嘧啶核苷類似物之口服配方治療癌症的方法
US20130158043A1 (en) * 2011-12-09 2013-06-20 Afraxis, Inc. Pak inhibitors for the treatment of cancer
EP2854811A1 (en) * 2012-05-31 2015-04-08 Amgen Inc. Use of amg 900 for the treatment of cancer
WO2013184572A1 (en) * 2012-06-04 2013-12-12 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
WO2014009319A1 (en) * 2012-07-11 2014-01-16 Boehringer Ingelheim International Gmbh Indolinone derivatives anticancer compounds
WO2014009318A1 (en) * 2012-07-11 2014-01-16 Boehringer Ingelheim International Gmbh 3-{3-[1 -(4-dimethylaminomethyl-phenylamino)-1 -phenyl-meth-(z)-ylidene]-2-oxo-2,3-dihydro-1 h-indol-6-yll-propynoic acid ethylamide and its use in the treatment of cancer
TR201904785T4 (tr) * 2012-08-09 2019-05-21 Celgene Corp (S)-3-(4-((4-MORFOLINOMETİL)BENZİL)OKSİ)-1-OKSOİZOİNDOLİN-2-il)PİPERİDİN-2,6-DİON HİDROKLORİDİN BİR KATI FORMU.
CN114366746A (zh) * 2012-08-09 2022-04-19 细胞基因公司 使用氧代异吲哚化合物治疗癌症
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
WO2014028560A2 (en) * 2012-08-14 2014-02-20 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
US20140120083A1 (en) * 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
AU2013360335B2 (en) * 2012-12-13 2017-12-07 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity

Also Published As

Publication number Publication date
US20200222379A1 (en) 2020-07-16
US20110129521A1 (en) 2011-06-02
JP2013512898A (ja) 2013-04-18
AU2010326699B2 (en) 2016-01-07
WO2011068522A1 (en) 2011-06-09
US10434090B2 (en) 2019-10-08
AU2010326699A1 (en) 2012-07-19
EP2506814A1 (en) 2012-10-10
US20120310183A1 (en) 2012-12-06
KR20120127580A (ko) 2012-11-22
EP2506814A4 (en) 2013-05-22
MX2012006128A (es) 2012-09-07
US8491927B2 (en) 2013-07-23
CN102711686A (zh) 2012-10-03
CA2782205A1 (en) 2011-06-09

Similar Documents

Publication Publication Date Title
JP2013512898A (ja) 低メチル化剤及びヒストン脱アセチル化酵素阻害剤を含む薬学的組成物
US20230255995A1 (en) Nicotinyl Riboside Compounds and Their Uses
US12178827B2 (en) Nicotinyl riboside compounds and their uses
US11286274B2 (en) Nicotinamide riboside derivatives and their uses
EP2603222B1 (en) Combinatory cancer treatment
RU2004124387A (ru) Системы введения лекарственных средств, содержащих рапамицин и его производные, которые предназначены для предупреждения и лечения сосудистых заболеваний
JP2013512898A5 (enExample)
US20240382512A1 (en) Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof
JP4624978B2 (ja) 血小板血症治療用製剤および治療方法
CN114469952B (zh) 特拉匹韦在制备malt1抑制剂、抗malt1依赖性肿瘤的药物中的应用及抗肿瘤药物
JP2016515625A (ja) 増殖性疾患を治療するための併用療法
WO2014022524A1 (en) Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
CN109310526B (zh) 普拉克索经皮贴片系统与用法
WO2016053989A2 (en) Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
KR20120104574A (ko) 티보자닙과 템시롤리무스의 조합물
KR20060123551A (ko) 최소한 한 개의 지방산을 포함하는 디하이드로피리딘 타입칼슘 길항제용 경피 전달 장치
Chatterji et al. Microtubules as Anti-Cancer Drug Targets

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140904

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141204

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150320

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150629

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160427

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160801

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160902

R150 Certificate of patent or registration of utility model

Ref document number: 6002040

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees